Document:

Exhibit 10.5

 

Palovarotene Program Consultancy AGREEMENT

 

between

 

Clementia Pharmaceuticals Inc., 4150 Ste-Catherine
St West, suite 550,

Montreal Quebec H3Z 2Y5 Canada

 

and

 

Luca Sangiorgi, MD PhD

Vicolo Malgrado 9, 40125 Bologna Italy

 

PREAMBLE

 

This Consultancy Agreement (“Agreement”)
is made by and between Clementia Pharmaceuticals Inc., (hereinafter “CLEMENTIA”), having a principal place of business
at 4150 Ste-Catherine Street West, Suite 550, Montreal, Qc, H3Z 2Y5, Canada and Luca Sangiorgi, MD, PhD (hereinafter “Dr.
Sangiorgi”), with principle address of Vicolo Malgrado 9, 40125 Bologna Italy. This Agreement is effective as of the date
indicated in Article 8 below and is entered into for the purpose of setting forth the exclusive terms and conditions by which CLEMENTIA
will acquire the services of DR. SANGIORGI for a defined scope and time.

 

	1.	Contract field

 

		1.1	DR. SANGIORGI is prepared to work for CLEMENTIA as a clinical consultant support of the palovarotene
development program as described in the Appendix hereto (hereinafter referred to as “CONTRACT FIELD”) according terms
and conditions as set forth in this Agreement.

 

		1.2	DR. SANGIORGI agrees that during the term of this Agreement, and any extension thereof, he will
not become a consultant or provide any services in the CONTRACT FIELD that might conflict with the obligations hereunder for any
individual or organization without the prior written consent of CLEMENTIA.

 

	2.	Best efforts

 

		2.1	CLEMENTIA hereby retains DR. SANGIORGI and DR. SANGIORGI hereby agrees to perform the services
set forth in Appendix A (the “Services”), as requested by CLEMENTIA from time to time and agreed to by DR. SANGIORGI.
The parties may more completely describe the Services in a separate service statement, proposal or other document mutually agreed
to by the parties. DR. SANGIORGI agrees to provide his reasonable best efforts to provide the Services under this Agreement.

    	 

    	

    

		2.2	In connection with his duties under this Agreement, DR. SANGIORGI is ready to undertake travel
that is reasonably necessary in order to render to CLEMENTIA his services in the CONTRACT FIELD, including but not necessarily
limited to travel to meetings.

 

	3.	Intellectual property

 

		3.1	All data and results (including but not limited to copyrights) which arise or are elaborated by
DR. SANGIORGI for CLEMENTIA in the course of rendering services in the CONTRACT FIELD will become the exclusive and unburdened
property of CLEMENTIA; any exploitation of these rights by CLEMENTIA or CLEMENTIA’s designee does not entitle DR. SANGIORGI
to any payment or indemnity other than the compensation described in Article 5 below. Accordingly, DR. SANGIORGI hereby assigns,
and agrees to assign from the time of creation, any right, title and interest he may have in any such data and results and waives
any and all moral rights he may at any time have therein.

 

		3.2	Should any inventions and/or improvements result from the performance of this Agreement, CLEMENTIA
shall be entitled, without any payment or indemnity whatsoever to DR. SANGIORGI other than the compensation described in Article
5 below, to file in its own name relevant patent applications, and the said inventions and improvements will become and remain
the unburdened property of CLEMENTIA. CLEMENTIA has the free right to use such inventions and/or improvements for research or commercial
activities. DR. SANGIORGI agrees to render to CLEMENTIA all requested assistance in this regard, including but not limited to the
execution of the signatures, papers and documents necessary for obtaining such patents.

 

	4.	Confidentiality/Publication

 

		4.1	Except as otherwise required by law or court order, during the validity of this Agreement and for
a period of five (5) years thereafter, DR. SANGIORGI shall keep in strict confidence all scientific, business and other information
received from CLEMENTIA or obtained or elaborated in connection with DR. SANGIORGI’s consultant services under this Agreement
(“Confidential Information”). DR. SANGIORGI will take all reasonable steps to maintain the confidentiality of the Confidential
Information, will not, without the prior written consent of CLEMENTIA, disclose the Confidential Information to any third party
nor use the Confidential Information for any purpose other than rendering the services hereunder in accordance with the provisions
hereof to the benefit of CLEMENTIA, provided that DR. SANGIORGI will not have any obligation to CLEMENTIA with respect to information
which:

 

		a)	is general public knowledge or becomes general public knowledge through no fault of DR. SANGIORGI;

 

		b)	was in DR. SANGIORGI’s possession on a non-confidential basis prior to its receipt thereof;

    	2

    	

    

		c)	is received by DR. SANGIORGI from any third party for use or disclosure without any obligation
to CLEMENTIA; or

 

		d)	can be shown to have been independently developed by DR. SANGIORGI without the use of any of the
Confidential Information.

 

		4.2	DR. SANGIORGI will not disclose the Confidential Information to any collaborators unless the latter
have a need to know the Confidential Information for the purpose and agree to be bound by obligations regarding the Confidential
Information as least as stringent as those imposed on DR. SANGIORGI hereunder.

 

		4.3	DR. SANGIORGI will, upon CLEMENTIA’s request, promptly return or destroy all Confidential
Information and documents made available to or elaborated by DR. SANGIORGI.

 

		4.4	The provisions of this Article 4 shall survive termination of this Agreement.

 

	5.	Compensation, Expenses, and Payment Terms

 

		5.1	CLEMENTIA undertakes to compensate DR. SANGIORGI for providing the services under this Agreement
a fee of [******] per hour. It is anticipated that DR. SANGIROGI will provide a maximum of 80 hours of consulting time per year
to this project. Time above 80 hours per year will require prior approval. DR. SANGIORGI shall submit to CLEMENTIA a compensation
Invoice at the end of each month that will include a summary description of the work performed for the month invoiced (a “Compensation
Invoice”). Each Compensation Invoice shall be accompanied by whatever supporting documentation is reasonably necessary to
aid CLEMENTIA in its review of such Compensation Invoice.

 

		5.2	CLEMENTIA shall pay each of DR. SANGIORGI’s correct Compensation Invoices within thirty (30)
days of receipt of such Invoice.

 

		5.3	It is anticipated that DR. SANGIORGI will incur normal expenses during the ·period of this
Agreement that are reasonably necessary to allow DR. SANGIORGI to render the services in the CONTRACT FIELD including, but not
limited to, travel (economy flight for domestic travel ≤ 6 hours, business or equivalent class for domestic travel greater than
6 hours and all international travel, taxi to and from the airport/railway station, accommodation), dining, and other reasonable
out-of-pocket expenses, which expenses shall be preapproved by CLEMENTIA. DR. SANGIORGI shall submit to CLEMENTIA an Invoice at
the end of each month that will include a summary description of the expenses DR. SANGIORGI incurred for the month invoiced in
connection with the provision of services hereunder (each, an “Expense Invoice”). Each Expense Invoice shall be accompanied
by whatever supporting documentation is reasonably necessary to aid CLEMENTIA in its review of such Expense Invoice.

 

		5.4	CLEMENTIA shall pay each of DR. SANGIORGI’s correct Expense Invoices within thirty (30) days
of receipt of such Invoice.

    	3

    	

    

		5.5	All invoices and correspondence should be addressed to:

 

Clementia Pharmaceuticals Inc.

Accounts Payable

4150 Ste-Catherine Street West

Suite 550

Montreal, Qc, H3Z 2Y5, Canada

 

and quoting the purchase order
number and line item.

 

		5.6	Upon receipt of proper documentation (Compensation Invoice and signed expense form including receipts),
Clementia will pay the invoice within thirty (30) days via check. All payments and correspondence to DR. SANGIORGI should be addressed
to:

 

Dr. Luca Sangiorgi

Vicolo Malgrado 9, 40125 Bologna Italy

 

		5.7	Any obligation of CLEMENTIA to make a payment to DR. SANGIORGI which arises prior to any termination
or expiration date of this Agreement shall survive termination of this Agreement.

 

	6.	Competence

 

		6.1	DR. SANGIORGI herewith declares that its activities under this Agreement and the Agreement itself
are not and will not at any time during the term of this Agreement be in violation with any rules, laws or the terms of any other
agreement previously entered into between DR. SANGIORGI and any third party.

 

	7.	General Terms

 

		7.1	DR. SANGIORGI’s status with CLEMENTIA shall be at all times during the term of this Agreement
that of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, or
employer-employee relationship. Further, DR. SANGIORGI is not an agent of CLEMENTIA and is not authorized to make any representation,
warranty, contract, and/or commitment on behalf of CLEMENTIA. No party shall have the authority to bind or obligate the other party
to this Agreement in any matter without the other party’s written approval.

 

		7.2	DR. SANGIORGI agrees that it, nor an employee of DR. SANGIORGI will receive any compensation or
assistance from any government, firm, person, or entity other than CLEMENTIA for the services DR. SANGIORGI renders in the CONTRACT
FIELD.

 

		7.3	This Agreement embodies the entire understanding among the parties hereto. This Agreement may not
be waived, assigned, amended, changed, modified, or altered unless mutually agreed upon in writing by both parties.

 

		7.4	In the event any provision of this Agreement is found to be legally unenforceable, such unenforceability
shall not prevent enforcement of any other provision of the Agreement.

    	4

    	

    

		7.5	Any notices required or permitted hereunder shall be provided as follows:

 

		a)	To CLEMENTIA:

Clementia Pharmaceuticals, Inc.

Attn: Donna Roy Grogan, MD, CMO

4150 Ste-Catherine St West, Suite 550,

Montreal, Quebec H3Z 2Y5 Canada

Fax: 514-940-3620

Email: dgrogan@clementiapharma.com

 

		b)	Dr. Luca Sangiorgi

Vic9lo Malgrado 9, 40125 Bologna Italy

Email: luca.sangiorgi@ior.it

 

		c)	Such notice shall be deemed to have been given when delivered or, if earlier (i) three (3) business
days after mailing by United States certified or registered mail, return receipt requested, postage prepaid, or (ii) one day after
it has been faxed or emailed with confirmation of delivery, in either case, addressed as required in this section.

 

		7.6	CLEMENTIA shall indemnify DR. SANGIORGI from any third party claim resulting from the provision
by DR. SANGIORGI of all services rendered in the CONTRACT FIELD for the term of this Agreement and any extension thereof, unless
such claim results from the negligence or wilful misconduct of DR. SANGIORGI.

 

	8.	Term and Termination

 

		8.1	The present Agreement shall come into force as from September 18, 2015 and shall remain in force
until September 18, 2018. Thereafter it can be extended by mutual written agreement.

 

		8.2	Either CLEMENTIA or DR. SANGIORGI may terminate this Agreement in the event of a material breach
of the Agreement by the other party that is not cured within thirty (30) days of written notice to the other party of such breach.
In addition, either party may terminate this Agreement for convenience with fifteen (15) days’ prior written notice to the
other party. If this Agreement is terminated for convenience with notice by CLEMENTIA, DR. SANGIORGI shall complete its present
work and CLEMENTIA shall compensate DR. SANGIORGI for such work.

 

	9.	Applicable Law and Jurisdiction

 

This Agreement shall be interpreted
and construed in accordance with the laws of Massachusetts. In case of controversies that cannot be settled amicably, the matter
shall be brought before the competent courts of Massachusetts, which shall have the exclusive jurisdiction.

    	5

    	

    

	10.	Benefit of the Agreement

 

This Agreement shall ensure to
the benefit of and be binding upon the parties’ respective heirs, executors, administrators, other legal representatives,
successors and assigns.

 

**REMAINDER OF PAGE INTENTIONALLY LEFT BLANK**

 

**SIGNATURES APPEAR ON FOLLOWING PAGE**

    	6

    	

    

	Montreal, 18 September 2015	
        Clementia Pharmaceuticals Inc.

       
	 	 
	 	        /Clarissa
                       Desjardins/

	 	        Clarissa Desjardins, PhD, CEO

	 	 
	Bologna, Italy 18 September 2015	

       
	 	 
	 	        /Luca
        Sangiorgi/

	 	        Luca Sangiorgi, MD, PhD

 

APPENDIX A

 

Contract Field.

 

DR. SANGIORGI will provide clinical consulting services in support
of CLEMENTIA’s palovarotene development program, and the potential role of palovarotene as a treatment for hereditary multiple
exostoses.

    	7Exhibit
10.6

 

AGREEMENT
FOR FEE-PER-SERVICE

 

This Agreement for fee-per-service
(this “Agreement’) is effective by and between Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical
company with an address at 4150 Sainte-Catherine St. West, Suite 550, Montreal, Quebec, H3Z 2Y5, in the person of Clarissa Desjardins,
PhD, CEO (“Clementia”), and Istituto Ortopedico Rizzoli, a public institution with registered office in Bologna,
Via di Barbiano n. 1/10 (CAP. 40136), Tax ID and VAT n. 00302030374, in the person of the Chief of SC Amministrazione della Ricerca,
Dr. Pierpaola D’Alessandro, [*****], authorized to the signature of this Agreement on behalf
of Legal Representative, by IOR Resolution nr. 199 of 2016, Aug 1st (“Rizzoli”/“IOR”) hereafter referred
as “Party”/“Parties”.

 

WHEREAS, Clementia
is a biopharmaceutical company dedicated to developing treatments for ultra-rare diseases, including Multiple Osteochondromas.

 

WHEREAS, Rizzoli
is one of the leading Italian Institutes specialized in the field of orthopedics and traumatology, having in 1981 been awarded
by the status of “Scientific Institute of recovery and care” by the Italian Ministry of Health. At Rizzoli is held
the structure “Medical Genetics and Rare Orthopaedic Diseases Department” (hereinafter “MG”) aims
to diagnose and take care of patients affected by rare skeletal dysplasias and other orphan diseases. In addition, this Unit, whose
scientific interest area is the field· of genetic and genomic research, collects and stores clinical and genealogical information
of patients (Disease Registries) integrated with the molecular results to perform genotype-phenotype correlations. In particular,
MG has implemented proprietary registries and databases (i.e. “Multiple Osteochondromas Registry”, “Diagnosis
Data Registry” etc.), hereinafter jointly defined as “REM”.

 

WHEREAS, Clementia
intends to obtain Registry data processing and analyses from Rizzoli’s REM for use in Clementia’s Multiple Osteochondroma
(“MO”) research program (the “Project”), as defined below, and with the goal of advancing research and
patient care in MO, which pertains to the area of activity of both parties.

 

NOW, THEREFORE,
the parties hereby agree as follows:

 

Article 1

Definitions and exhibits

 

1.1For purposes
of this Agreement, the following terms shall have the meanings specified below:

 

“Effective date”
shall mean the date referred to in art. 9.1 where this present Agreement becomes legally binding.

 

“Registry Data
Analyses” shall mean aggregated demographic, clinical, genetic and other aggregate evaluation of anonymous data requested
by Clementia and extracted from REM, as more particularly described in Exhibit A (Technical Annex).

 

“Project”
shall mean an iterative exploration of data contained in the REM to design the development program with the aim to improve MO patients’
treatments and protocols.

    	 

    	

    

“Scientific
Report” shall mean a document, in paper or digital format, that describes the process, progress and results of a scientific
research. It might also include recommendations and conclusions of the research and implemented guidelines. This document usually
includes the Introduction, the Experimental section (where the materials and methods used are described), the Result section where
the achieved outcomes are described, the Discussion of results and a Reference section.

 

“Proprietary
Information” shall mean the confidential and proprietary information of a Party: (i) which is disclosed by such Party
(the “Disclosing Party”), to the other Party (the “Receiving Party”) hereunder; (ii) that
is disclosed during the execution of the Analyses, independent of its express classification as “Confidential “. Proprietary
Information shall not include information that (a) is in possession of the Receiving Party at the time of disclosure thereof as
demonstrated by written records; (b) is or later becomes part of the public domain through no fault of the Receiving Party; (c)
is received by the Receiving Party from a third party having no obligation of confidentiality to the Disclosing Party; (d) is developed
independently by the Receiving Party without use of Proprietary Information; (e) is required by law or regulation to be disclosed;
provided, however, that the Receiving Party has provided written notice to the Disclosing Party promptly to enable the Disclosing
Party to seek a protective order or otherwise prevent disclosure of such information; or (f) is disclosed by the Receiving Party
in accordance with the terms of the Disclosing Party’s prior written approval. All results of the Project shall be deemed
to be Proprietary Information of Clementia and the MO Registry shall be deemed the Proprietary Information of Rizzoli.

 

“Background”
shall mean all products, methods, new knowledge, technology and inventions, patentable/copyrightable or not, and other intellectual
property that already exists prior the Effective Date of this Agreement.

 

“Project Results”
shall mean all and any intellectual property rights in the Analyses and in the final Scientific Report

 

1.2Technical annex
(Exhibit A) shall be considered as an integral part of the Agreement.

 

Article 2

Object of the Agreement

 

2.1Clementia appoints
Rizzoli, that accepts, to perform research activities that consist of elaborations and analyses on data extracted from Rizzoli‘s REM. In particular, IOR involvement should include a complex selection of anonymized case studies with multiple data extrapolation
from REM IT platform, according to Clementia specifications and requirements (see Exhibit A) . Such research activities could include
revaluations of clinical charts, radiological images and surgical folders revaluations. Clementia will not receive any data extrapolated
form REM IT: the output that IOR should provide will exclusively be a Scientific Report (as foreseen at art 4), resulting from
this internal multistep process, that includes data cleaning, data processing and data analyses.

    	2

    	

    

2.2Such Registry
Data Analyses shall be performed on anonymized information/data/records according to the modalities listed and described in the
Technical Annex (Exhibit A).

 

2.3The main purpose
of the Registry Data Analyses report is to increase the knowledge on MO disease in order to provide a chance to better understand
natural history, disease progression, allowing researchers to establish adequate management and specific follow-ups for these patients.
As a consequence, the required service of data analysis is intended to result in more adequate and personalized treatments, reducing
time and cost of specialists with a significant impact on Public Health.

 

Article 3

Scientific and Administrative contacts

 

3.1Rizzoli Chief
Scientific Investigator responsible for the Analyses is Dr. Luca Sangiorgi (Head of Rizzoli MD), responsible also for data security.
Contacts: email: luca.sangiorgi@ior.it; phone: +39 051 6366342

 

3.2The person in
charge on behalf of Clementia for all scientific matters pertaining to the execution of the Analyses (“Project manager”)
is Dr. Donna Grogan (Chief Medical Officer), responsible also for data security. Contacts: email: dgrogan@clementiapharma.com ,
phone: 857-226-5582.

 

3.3Rizzoli Administrative
contacts are: SC Amministrazione della Ricerca - Dr. Pierpaola D’Alessandro; address: Istituto Ortopedico Rizzoli , via di
Barbiano, 1/10, CAP 40136, Bologna (Italy); email: sars@ior.it; phone +39 0516366732; registered mail/PEC: ufficio.ricerca@pec.ior.it;
fax +39 0516366540.

 

3.4Clementia Administrative
contacts are: Jeff Packman, Chief Development Officer; jpackman@clementiapharma.com; 857-226-5581 .

 

Article 4

Implementation procedures

 

4.1Rizzoli will
perform services at MG Structure (via di Barbiano 1/10, 40136 Bologna) according to terms and conditions agreed for in Exhibit
A.

 

4.2As activities
of art. 2 are concerned, the Rizzoli Chief Scientific Investigator declares that the Authorizations to the implementation of the
EM has been obtained by Rizzoli’s Ethical Committee on 2008, July 12nd (prot gen nr. 18139), and subsequent documentation
updates and revisions.

 

4.3Legal Authority
Rizzoli hereby certifies that it has the legal authority and right to use the Registry Data to implement the Analyses, as contemplated
by this Agreement Parties agree that none report should be considered as a kind of validation or authentication released by Public
Authorities.

    	3

    	

    

4.4Registry Data
Analyses: to the extent allowed by law, Rizzoli shall provide Clementia with the Registry Data Analyses report to be used by Clementia
solely in accordance with Article 6 of this Agreement The Parties agree that Rizzoli will perform Analyses on the Registry Data,
making all the data totally anonymous in accordance with applicable law, and that the identity of individuals whose data is incorporated
into the REM shall be maintained completely in confidence by Rizzoli, applying all the technical measures to avoid patient identification
and not provided to Clementia hereunder. In the event that Clementia, in connection with the Project, inadvertently learns the
identity of an individual or individuals from whom information was obtained for the REM, Clementia agrees to maintain such individuals’
identities in strict confidence.

 

4.5In the implementation
of the Data Analyses, Rizzoli - in person of the IOR Chief Scientific Investigator - must keep Clementia updated - through its
Project Manager - on the progress of the Analyses, including but not limited to relevant preliminary results.

 

4.6Should events
of any kind interrupt the aforementioned Analyses, Rizzoli - in person of the Chief Scientific investigator - must inform Clementia
- in person of Project Manager - in writing by registered mail with return receipt, and/or by e-mail within four (4) working days.

 

4.7After the conclusion
of activities agreed upon by the Fee-per-Service - it is intended that research activities will take at least 4 months from the
date of last signature of the Contract - , Rizzoli Chief Scientific Investigator shall send to Clementia Project Manager a final
Scientific Report by registered mail with return receipt/PEC.

 

4.8Rizzoli will
provide Clementia with a preliminary Scientific Report by email to be reviewed by Clementia, and within fifteen (15) days from
delivery of the preliminary report - Clementia Project Manager may ask to Rizzoli Chief Scientific investigator for elucidations
and/or further information, integrations, etc. Rizzoli Chief Scientific Investigator should answer to the request for elucidations
within thirty (30) days from arrival of the request. Should Clementia not require any amendments within fifteen (15) days form
arrival of the preliminary Report, Rizzoli will send to Clementia the final Report, and the activity shall be considered fulfilled.

 

4.9Rizzoli Chief
Scientific Investigator may assign qualified staff members and contract staff to jointly work on the project. The choice of Rizzoli
staff for the Analyses is the sole prerogative of Rizzoli. Appointed staff cannot lay claims for an employment contract with Clementia,
the latter being completely independent of the employment contract between the former and Rizzoli.

 

Article 5

Compensation and method of payment

 

5.1Clementia undersigns
to pay Rizzoli the sum of [******]+ VAT for the activity described in this Agreement,
according to the following method and terms of payment:

    	4

    	

    

		·	50% of the total cost, within thirty (30) days from receipt of invoice – such invoice to be
issued by Rizzoli to Clementia at the signature of this Agreement;

 

		·	50% of the total cost, within thirty (30) days from receipt of invoice – such invoice to be
issued Rizzoli to Clementia upon completion of the activities as foreseen at art. 4.

 

5.2Payments must
be settled within thirty (30) days from receipt of invoice, by bank draft to: UNICREDIT BANCA SPA - Agenzia Bologna Pupilli, Via
Pupilli, 1 - 40136 Bologna, [*****]. Should payment not be settled in due date, legal interest rates
will run from that date.

 

Article 6

Use of the Registry Data Analyses

 

6.1Use of Registry
Data Analyses by Clementia: Clementia agrees to use the Registry Data Analyses report for purposes of the Project only, as indicated
at art. 1.1 and in accordance with the terms of this Agreement. In particular, the Analyses is for Clementia internal purpose only,
is not intended to be published and is exclusive and sole proprietary of Clementia. Clementia shall use the Analyses and the data
for the rating and for regulatory purposes only. No commercial or advertising use has been done in the past and shouldn’t
be done for the future.

 

6.2Distribution
of Registry Data Analyses: Clementia shall not provide access to or distribute the Registry Data Analyses report to any third party
other than employees, agents, consultants, regulatory authorities and professional advisors of Clementia, any collaborator or any
third party contractor engaged by Clementia, in each case who are working on the Project and who are bound by obligations comparable
to those set forth in Article 8 or to regulatory authorities.

 

6.3Use of Registry
Data Analyses and of Registry Data by Rizzoli: the Registry Data Analyses report is provided by Rizzoli to Clementia on a non-exclusive
basis and Rizzoli shall be free to use and to supply to third parties such Analyses and the Registry Data from the REM as Rizzoli
may in its sole discretion decide, subject to Article 8.

 

Article 7

Intellectual Property Rights

 

7.1Ownership of
Project Results: Project results, shall vest in, be the property of, and shall be owned exclusively by, Clementia.

 

7.2Background Intellectual
Property: It is recognized and understood that the Background of each Party is the separate property of Clementia and Rizzoli and
that is not affected by this Agreement. Neither party shall have any claims or rights in such separate Background (inventions,
technology or other intellectual property) except as necessary to for the performance of this Agreement.

    	5

    	

    

7.3Except as expressly
set forth herein no rights or licenses are granted by either party hereunder.

 

Article 8

Proprietary Information and confidentiality

 

8.1The Parties know
and agree that Rizzoli will analyse and elaborate data that are registered with the Rizzoli due to applicable national legislation.

 

8.2Confidentiality:
from time to time during the term of this Agreement, the Disclosing Party in connection with activities conducted hereunder, may
disclose Proprietary Information to the Receiving Party. The Receiving Party will use the Proprietary Information for purposes
of this Agreement only and will not further use or disclose the Proprietary Information without the prior, written consent of the
Disclosing Party.

 

8.3Return of Proprietary
Information: upon expiration or termination of this Agreement, the Receiving Party, if requested by the Disclosing Party, shall
return or at Disclosing Party’s option destroy, all copies of Proprietary Information disclosed, and all other materials
provided by the Disclosing Party to the Receiving Party under this Agreement; provided, that the Receiving Party may retain one
copy of such other Confidential Information and such materials on a confidential basis for archival purposes only.

 

8.4Use of Name:
No party to this Agreement shall use the name of any other party or of any staff member, employee or student of any other party
or any adaptation thereof in any advertising, promotional or sales literature or in any publicity without the prior written approval
of the party or individual whose name is to be used.

 

Article 9

Term and Termination

 

9.1Term: this Agreement,
unless earlier terminated as provided herein, shall be effective as of the Date of last signature and will terminate on 15.12.2018,
unless extended in writing by mutual agreement prior to the termination date.

 

9.2Termination at
will: either Party may, at any time, terminate this Agreement by giving not less than thirty (30) days’ prior written notice
(by registered mail with return receipt/PEC) to the other.

 

9.3Termination for
Breach: if either party materially breaches any representation, term or condition of this Agreement and fails to remedy such breach
within thirty (30) days after receipt of notice in writing of such material breach from the other Party, the non-breaching Party,
may, in addition to any other remedies that such party may have in law or in equity, terminate this Agreement by sending written
notice (by registered mail with return receipt/PEC) of termination to the other Party.

 

9.4Effect of Termination:
for purposes of clarity, the parties acknowledge that termination of this Agreement shall not prevent Clementia’s continued
use any Registry Data Analyses provided prior to termination.

    	6

    	

    

Article 10

Representations and Warranties; Liability and Indemnification

 

10.1Representations
and Warranties of Rizzoli: Rizzo Ii represents and warrants that (a) there is no agreement in effect on the Effective Date between
Rizzoli and any party which prohibits Rizzoli from granting to Clementia the rights set forth hereunder; (b) Rizzoli has the legal
right, authority and power to enter into this Agreement and meet the obligations set forth herein; and (c) Rizzoli has obtained
informed consent from all patients and human subject volunteers in accordance with Article 4.3 of this Agreement and according
to all applicable law and regulations.

 

10.2No Other Representations:
OTHER THAN AS SET FORTH IN THIS AGREEMENT, RIZZOLI MAKES NO REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY KIND , EITHER EXPRESS
OR IMPLIED, WITH RESPECT TO THE REGISTRY DATA AND TO SUCH REGISTRY DATA ANALYSES. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

10.3Limitation of
Liability: neither Party shall be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for
any economic loss or other loss of turnover, profits, business or goodwill or any loss, damage, costs or expenses of any nature
whatsoever incurred or suffered by the other Party or its Affiliates of an indirect or consequential nature arising out of or in
connection with this Agreement.

 

10.4Indemnification
by Clementia: Clementia assumes all liability for damages that may arise from its use of the Registry Data Analyses Clementia agrees
to indemnify, defend, and hold harmless Rizzoli and its representatives, employees, and agents (the “Rizzoli Indemnitees”)
against all losses, expenses (including without limitation any legal expenses), claims, demands, suits, or other actions arising
from Clementia’s activities hereunder except to the extent any of the foregoing was directly caused by the negligence or
willful misconduct of the Rizzoli Indemnitees.

 

10.5Indemnification
by Rizzoli: Rizzoli agrees to indemnify, defend, and hold harmless Clementia and its representatives, employees, and agents (the
“Clementia Indemnitees”) against all losses, expenses (including without limitation any legal expenses), claims, demands,
suits, or other actions arising from any breach by Rizzoli of any of its representations or warranties made herein, except to the
extent the same was directly caused by the negligence or willful misconduct of the Clementia Indemnitees.

 

Article 11

Anticorruption rules

 

11.1The Parties
undertake to comply with all applicable anti-corruption and transparency law rules, according to Italian laws (DL 190/201 , D.Lgs
33/2013 and D.Lgs. 231/01) liability of corporate bodies and, in any case, to refrain from any behavior that is prohibited by the
Italian rules or other applicable regulations against corruption (collectively “Rules against Corruption”).

    	7

    	

    

11.2Parties acknowledge
that any breach of Rules against Corruption will authorize the non-breaching Party to immediately terminate the Agreement, as 1456
of Italian Civil Code.

 

Article 12

Force Majeure

 

12.1Rizzoli is not
responsible for losses, damages, delays or non-execution of tests, if these are caused by unpredictable accidents or force majeure.

 

Article 13

Processing of personal data

 

13.1Rizzoli will
handle processing, diffusion and communication of personal data concerning this Agreement within the scope of its institutional
objectives and in accordance with the current law and regulations.

 

13.2Clementia must
process all personal data coming from Rizzoli only for purposes set out in this Agreement in accordance with the applicable laws
and regulations.

 

Article 14

Governing laws and Jurisdiction

 

14.1The Parties
agree that English shall be the official language of this Agreement.

 

14.2Parties agree
that any issues related to any matter which is not provided for in this Agreement, shall be preliminary discussed truthfully and
in good faith for settlement purposes.

 

14.3In case of dispute
this agreement shall be governed by the Italian Law exclusively.

 

Article 15

Miscellaneous

 

15.1Amendments:
no amendments or changes to or waivers of this Agreement shall be effective unless made in writing and duly executed by an authorized
signatory on behalf of each Party.

 

15.2Entire Agreement:
this Agreement embodies the entire understanding and agreement between the Parties with respect to the subject matter hereof and
supersedes all prior agreements and understandings between the parties hereto, whether written or oral, relating to the subject
matter hereof.

 

15.3Assignment:
this Agreement shall not be assignable by either party without the prior written consent of the other Party, which consent shall
not be unreasonably withheld or delayed. Any attempted assignment in contravention of the foregoing shall be void and of no force
or effect.

    	8

    	

    

15.4Notices: any
notices required to be given or which shall be given under this Agreement shall be in writing delivered by recognized overnight
courier service, personal delivery, telecopier (with evidence of receipt), first class mail or by certified or registered mail
(PEC) addressed to the parties as shown at article 3.3 and 3.4.

 

15.5Signatures:
this Agreement may be executed in counterparts. This Agreement may be executed by the signatories hereto and sent electronically,
the electronic copy of said signature being provisionally accepted: then the original hard copy should be sent by courier service.
This Agreement may also be executed by the signatories hereto by electronic signatures in accord with the standards and practices
established by the internal procedures of the Parties. E-signatures will have the same full force and effect as an original signature.

 

15.6Registration
expenses: this Agreement shall be registered for use and at a fixed rate in accordance with artt. 5 and 39 of DPR n. 131/86. Except
as set forth in Article 5, each Party will bear its own expenses under this Agreement.

 

IN WITNESS WHEREOF,
the undersigned have executed this Agreement.

 

	 	CLEMENTIA PHARMACEUTICALS, INC.
	 	 	 	 
	 	Date:                         April 27, 2017                           	 
	 	 	 	 
	 	By:	/Clarissa Desjardins/	 
	 	 	Name: Clarissa Desjardins, PhD	 
	 	 	Title:   Chief Executive Officer	 
	 	 	 	 
	 	ISTITUTO ORTOPEDICO RIZZOLI	 
	 	 	 	 
	 	Date:                         28 MAR 2017                           	 
	 	 	 	 
	 	By: 	/Pierpaola D’Alessandro/	 
	 	 	Name: Dr. Pierpaola D’Alessandro	 
	 	 	Title:   Chief of SC Amminstrazione della Ricerca	 

 

	Seen and Approved	 
	 	 	 	 
	CLEMENTIA PHARMACEUTICALS, INC.	 
	 	 	 	 
	By:	 	/ Donna Grogan/ 27 April 2017	 
	 	 	Dr. Donna Grogan	 
	 	 	 	 
	ISTITUTO ORTOPEDICO RIZZOLI	 
	 	 	 	 
	By:	 	/Luca Sangiorgi/ 28 MAR 2017	 
	 	 	Dr. Luca Sangiorgi	 

    	9

    	

    

The Parties acknowledge
to be bound by each contract clause and specifically approve the following:

 

Article 5 – Compensation and method of payment

Article 6 – Use of the Registry Data Analyses

Article 7 – Intellectual Property Rights

Article 8 – Proprietary Information and confidentiality

Article 9 – Term and termination

Article 11 – Anticorruption rules

Article 14 – Governing laws and Jurisdiction

Article 15.3 – Assignment

 

	 	CLEMENTIA PHARMACEUTICALS, INC.
	 	 	 	 
	 	Date:                         April 27, 2017                           	 
	 	 	 	 
	 	By:	/Clarissa Desjardins/	 
	 	 	Name: Clarissa Desjardins, PhD	 
	 	 	Title:   Chief Executive Officer	 
	 	 	 	 
	 	ISTITUTO ORTOPEDICO RIZZOLI	 
	 	 	 	 
	 	Date:                         28 MAR 2017                           	 
	 	 	 	 
	 	By: 	/Pierpaola D’Alessandro/	 
	 	 	Name: Dr. Pierpaola D’Alessandro	 
	 	 	Title:   Chief of SC Amminstrazione della Ricerca	 

 

	Seen and Approved	 
	 	 	 	 
	CLEMENTIA PHARMACEUTICALS, INC.	 
	 	 	 	 
	By:	 	/ Donna Grogan/ 27 April 2017	 
	 	 	Dr. Donna Grogan	 
	 	 	Chief Medical Officer	 
	 	 	 	 
	ISTITUTO ORTOPEDICO RIZZOLI	 
	 	 	 	 
	By:	 	/Luca Sangiorgi/ 28 MAR 2017	 
	 	 	Dr. Luca Sangiorgi	 

    	10

    	

    

Exhibit A

Technical Annex

 

The Structure that performs
the Research Activity is Rizzoli Medical Genetics and Rare Orthopaedic Diseases Department and CLIBI Laboratory (Responsible: Dr.
Luca Sangiorgi).

 

All the activities will
be conducted by Medical Genetics and Rare Orthopaedic Diseases Department and CLIBI Laboratory personnel (Head/Scientific Responsible:
dr. Luca Sangiorgi)

 

1)INTRODUCTION

 

The data that will processed
and analysed will be included in the Scirntifico Report, that will be sent to Clementia according to this agreement, collected
on REM registry.

 

Multiple Osteochondromas
(MO) is an autosomal dominant disease characterized by the formation of multiple cartilage-capped bone tumours (defined osteochondromas,
OCs) typically located in the long bones. OCs are rarely present at birth and grow in number and size during childhood, until completed
skeletal maturity. The great variability in size and number of lesions reflects the MO clinical heterogeneity which is characterized
by pain, abnormal skeletal growth, decreased range of motion, and deformities. The most serious complication is malignant transformation
of OCs into secondary peripheral chondrosarcomas (1-5%). Actually, surgery is the only available treatment with several operations
in patient lifespan (average 3) and multiple x-ray is the method of choice in patient monitoring.

 

MO is mostly caused
by heterozygous mutations in the heparan sulfate (HS)-synthesizing enzymes EXT1 or EXT2, implicated in the control of cartilage
growth during endochondral ossification; they catalyse polymerization of heparan sulfate glycosaminoglycans (HSGAGs) chains, which
are covalently linked to core proteins, thus forming proteoglycans. Even if some EXT mutations are reported to lead to active enzyme
isoforms, they are supposed to modify the activity of HS polymerases thus leading to the production of HS chains different from
wild-type status; unfortunately, these observations have never been demonstrated in MO patients and the biochemical effect of specific
EXT 1/2 mutations is currently unknown.

 

As known, MO is characterized
by a wide clinical intra- and inter-familial variability, currently unexplained at molecular level. Since various genotype-phenotype
correlation studies failed to identify specific associations between EXT mutations and clinical manifestations. it is likely that
secondary factors influence survival and growth of the lesions.

 

Since EXT mutations
cannot explain all MO genetic aetiology and OC growth is extremely variable in site, size and number, we decided to collect structured
data in a Registry in order to promote more productive genotype-phenotype correlation, to study MO epidemiology and natural history
and to provide our data analyses for researches and studies.

 

As a matter of fact.
a Disease Registry is a collection of personal, clinical, genetic data of patients.

 

Many definitions are
available for registry. The US Agency for Healthcare Research and Quality define a Registry as “an organized system that
uses observational study methods to

    	11

    	

    

collect uniform data
(clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and
that serves one or more predetermined scientific, clinical or policy purposes” and WHO described in 1974 it as “a file
of documents containing uniform information about individual persons, collected in a systematic and comprehensive way, in order
to serve a pre-determined scientific, clinical or policy purpose”. Many other descriptions can be found internationally,
but them all share few main concepts: a) the realization of an organized system, b) denoted by uniformity of data, c) related to
a specific disease or precise group of patients d) and finalized to explicit purposes.

 

More in details a patient
registry is a powerful tool composed of interconnected elements that work jointly in order to create an organized collection of
information. The word “registry” is composed of two related connotations, the act of register and the entry in a repository
and effectively both meanings are involved in a patient registry. The items collected, like clinical data, laboratory test results,
anamnestic history and so on , are primary to the scope, but them all are connoted by consistent uniformity both in the nuance
of data type composition and in structuring of data themselves.

 

Starting from 2003 the
Medical Genetics and Rare Orthopedic Diseases Department started a collection of data from patients and families affected by Rare
Diseases (in particular skeletal dysplasia) and in the subsequent years stared to standardize this data collection and in collaboration
with CLIBI Laboratory established the REM (Registry for Mutliple Ostechondromas Disease).

 

2)DESCRIPTION OF THE RESEARCH ACTIVITIES (preliminary
and Analyses)

 

Research activities
(internal to IOR) are composed of multiple steps:

 

		1.	a complex selection of case studies includible in this study;

 

		2.	according to Clementia specifications and requirements, some multiple data extrapolations from REM to .xls file (or similar
format. such as .cvs file );

 

		3.	clinical chart, radiological images and surgical folders revaluations;

 

		4.	a multistep process of data elaboration, that includes data cleaning, data processing and data analyses.

 

All these steps will
be processed after a preliminary point by point evaluation of required data analyses (listed below)

 

After the internal research
activities, IOR will implement the Scientific Report, as output to be provided to Clementia. The scientific report will not include
any personal data that could allow to identify (directly or indirectly) any patient included in the REM.

 

2.1AIM

 

Research activities
of this agreement aim to increase the knowledge on MO disease, mainly by an epidemiologic point of view, taking into account underage
patients.

    	12

    	

    

This will be a preliminary
evaluation, helpful to comprehend the disease evolution and pathological development of Osteochondromas.

 

2.2OBJECT OF THE ANALYSES

 

The data analyses imply
a complex selection of interesting cases, according to Clementia specifications and requirements (see 2.4 Data to analyse). Moreover,
REM extrapolated data will be checked, cleaned, processed and at least analysed, following the sequent steps:

 

		·	Evaluation of demographic data categorized by age groups

 

		·	Evaluation of clinical data categorized by age groups

 

		·	Evaluation of radiographical data categorized by age groups

 

		·	Disease Evolution studies by age groups

 

		·	Number, sites, localizations of OC analyzed by age groups

 

		·	Number and type of surgical interventions

 

		·	Patients age distribution according to surgical interventions (categorized by age groups)

 

		·	Evaluation of interrelations between OC dimension and functional outcomes (pain, deformities, limitations,
etc.)

 

All mentioned steps
are epidemiological issues composed of more questions.

 

2.3POPULATION UNDER STUDIES

 

All paediatric patients
(<18 age) affected by MO disease.

 

2.4DATA TO ANALYZE

 

In the following pages
there are listed the data that Clementia requires to be included in the Analyses.

 

MO Registry Questions

 

Demographics:

 

		·	Number of children according to the following age categories: 0-6 years, 7-12 years, 12-18 years.

 

		·	Number of males/females by the above age categories, and overall.

 

		·	Number of children per disease stage, by the above age categories and overall.

    	13

    	

    

		·	The mean (median, range) patient stature by percentile of normal, by the above age categories and
overall.

 

Disease Characteristics - by age categories and overall:

 

		·	Mean, (median, range) age at diagnosis.

 

		·	What is the mutation type?

 

		·	Mean, (median, range) age at onset of first OC.

 

		·	What is the stage of disease upon entry into the registry?

 

		·	How are functional limitations assessed for the purposes of disease stage classification?

 

		·	How are deformities assessed for the purposes of disease stage classification?

 

		·	How are OCs assessed for categorization of disease stage:

 

		o	Physical examination?

 

		o	Ultrasound?

 

		o	MRI?

 

		o	CT scan?

 

		o	Other?

 

		·	What are the locations of OCs?

 

		o	Are OC typically bilateral or unilateral? Should the data requested below be provided by right/left
regions, or just by region?

 

		o	What are the locations of OCs by age and by age category?

 

		o	What are the locations of OCs by disease stage?

 

		·	What is the mean (median, range) follow-up time?

 

		·	What percent of subjects, by age category and overall, have progressed:

 

		o	From Stage 1 to Stage 2

 

		o	From Stage 1 to Stage 3

 

		o	From Stage 2 to Stage 3?

    	14

    	

    

		·	What is the mean (median, range) time to progression:

 

		o	From Stage 1 to Stage 2

 

		o	From Stage 1 to Stage 3

 

		o	From Stage 2 to Stage 3

 

		·	What medications are used for disease management?

 

		·	What is the percentage of subjects by age category and overall that underwent at least one surgical
excision of OC?

 

		o	Mean (median, range) age of the first surgery

 

		o	What were the reasons for surgery?

 

		·	What is the percentage of subjects by age category and overall that underwent at least one surgical
procedure to correct deformity?

 

		o	Mean (median, range) age of the first surgery

 

		·	What is the mean (median, range) number of surgical procedures performed overall, and by age category?

 

		·	Is there a relationship between number and/or size of OCs as noted by physical examination and/or
imaging and functional outcome (local pain, deformities, and/or decreased ROM)?

    	15

    	

    

	Table 1. ROI Disease Registry Investigation (Age Category)
	 	 	0-6 years	7-12 years	12-18 years	Overall
	Patients	N %	 	 	 	 
	Sex, n (%)	Males

Females	 	 	 	 
	Mutation type, n (%)	EXT 1

EXT 2	 	 	 	 
	Stature	Percentile normal	 	 	 	 
	Age at diagnosis, years	Mean

Median range	 	 	 	 
	Age at first OC, years	Mean

Median (range)	 	 	 	 
	Follow-up time, months	Mean

Median (range)	 	 	 	 
	Stage at entry into the registry, n (%)	Stage 1

Stage 2

Stage 3	 	 	 	 
	Current stage, n (%)	Stage 1

Stage 2

Stage 3	 	 	 	 
	Stage progression, n(%)	Stage 1 to Stage 2

Stage 1 to Stage 3

Stage 2 to Stage 3	 	 	 	 
	Time to Stage progression, years	Mean

Median (range)	 	 	 	 
	At least one surgical excision of OC, n (%)	 	 	 	 	 
	At least one surgery to correct deformity, n (%)	 	 	 	 	 
	Number of surgical procedures	Mean

Median (range)	 	 	 	 
	Age at first surgery	Mean

Median (range)	 	 	 	 

    	16

    	

    

	Table 1. ROI Disease Registry Investigation (Age Category)
	 	 	0-6 years	7-12 years	12-18 years	Overall
	OC location at entry into the registry, n (%)	Ribs

Femur

Radius

Ulna

Carpal bones

Metacarpal bones

Spine

Iliac crest

Proximal femur

Distal femur

Proximal tibia

Distal tibia

Proximal fibula

Distal fibula

Tarsal bones

Metatarsal bones	 	 	 	 
	Osteochondromas at entry into the registry, n (%)	 	 	 	 	 
	Osteochondromas at follow-up, n (%)	 	 	 	 	 
	Time to OC progression	Mean

Median (range)	 	 	 	 
	Deformities at entry into the registry, n (%)	 	 	 	 	 
	Deformities at follow-up, n (%)	 	 	 	 	 
	Time to deformity progression	Mean

Median (range)	 	 	 	 
	Functional limitations at entry into the registry, n (%)	 	 	 	 	 
	Functional limitations at follow-up, n (%)	 	 	 	 	 
	Time to functional limitations	Mean

Median (range)	 	 	 	 

    	17

    	

    

	Table 2. ROI Disease Registry Investigation (Disease Stage)
	 	 	Stage 1	Stage 2	Stage 3	Overall
	OC location at entry into the registry, n (%)	Ribs

Femur

Radius

Ulna

Carpal bones

Metacarpal bones

Spine

Iliac crest

Proximal femur

Distal femur

Proximal tibia

Distal tibia

Proximal fibula

Distal fibula

Tarsal bones

Metatarsal bones	 	 	 	 

    	18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]